Used in cancer immunotherapy to enhance T-cell activation and anti-tumor immune responses. Targets the OX40 receptor on T cells, promoting their proliferation, survival, and effector function. Investigated in clinical trials as a monotherapy and in combination with other immunotherapies such as checkpoint inhibitors to improve outcomes in solid tumors. Shows potential in overcoming immune suppression within the tumor microenvironment.